BioCentury | Sep 30, 2013
Company News

Tenex board of directors update

Tenex Health Inc. , Lake Forest, Calif. Business: Musculoskeletal Appointed: Doug Kohrs, a director, as executive chairman, formerly CEO of Tornier N.V.; he succeeds Ivan Mijatovic, who remains a director and becomes interim CFO WIR Staff...
BioCentury | Jun 25, 2007
Strategy

SHP building business

...from FDA (see B12). Novartis (NVS; SWX:NOVN, Basel, Switzerland) launched guanfacine under the brand name Tenex...
BioCentury | Jan 31, 2005
Strategy

PDLI's integrated pipeline

...coronary artery disease (CAD) Mkt Sectral acebutolol cardioselective beta blocker Hypertension and ventricular arrhythmias Mkt Tenex...
BioCentury | Jan 31, 2005
Strategy

A NRDO exits

...disease; Sectral acebutolol, a cardioselective beta blocker for treatment of hypertension and ventricular arrhythmias; and Tenex...
BioCentury | Sep 6, 2004
Finance

Ebb & Flow

...in the round were Draper Fisher Jurvetson; ePlanet Ventures; CDIB BioScience; Wasatch Venture Fund; and Tenex...
BioCentury | Sep 2, 2004
Financial News

Zars raises $19 million

...by Draper Fisher Jurvetson. Other investors included ePlanet Ventures; CDIB BioScience; Wasatch Venture Fund; and Tenex...
BioCentury | Jun 28, 2004
Financial News

Virogenomics spins out Artielle

...companies. Artielle also raised $4 million in a series A round with Sanderling; UV Partners; Tenex...
BioCentury | May 28, 2002
Company News

ESP Pharma, Wyeth deal

...million in 2001 sales, include Cardene IV for hypertension, Sectral for hypertension and ventricular arrhythmias, Tenex...
BioCentury | May 22, 2002
Financial News

ESP Pharma raises $28 million

...million in 2001 sales, include Cardene IV for hypertension, Sectral for hypertension and ventricular arrhythmias, Tenex...
BioCentury | Jan 3, 2002
Financial News

Myogen raises $14 million

...Perseus-Soros BioPharmaceutical Fund; China Development Industrial Bank; Hunt Ventures; Silicon Valley Bank; and affiliates of Tenex...
Items per page:
1 - 10 of 13
BioCentury | Sep 30, 2013
Company News

Tenex board of directors update

Tenex Health Inc. , Lake Forest, Calif. Business: Musculoskeletal Appointed: Doug Kohrs, a director, as executive chairman, formerly CEO of Tornier N.V.; he succeeds Ivan Mijatovic, who remains a director and becomes interim CFO WIR Staff...
BioCentury | Jun 25, 2007
Strategy

SHP building business

...from FDA (see B12). Novartis (NVS; SWX:NOVN, Basel, Switzerland) launched guanfacine under the brand name Tenex...
BioCentury | Jan 31, 2005
Strategy

PDLI's integrated pipeline

...coronary artery disease (CAD) Mkt Sectral acebutolol cardioselective beta blocker Hypertension and ventricular arrhythmias Mkt Tenex...
BioCentury | Jan 31, 2005
Strategy

A NRDO exits

...disease; Sectral acebutolol, a cardioselective beta blocker for treatment of hypertension and ventricular arrhythmias; and Tenex...
BioCentury | Sep 6, 2004
Finance

Ebb & Flow

...in the round were Draper Fisher Jurvetson; ePlanet Ventures; CDIB BioScience; Wasatch Venture Fund; and Tenex...
BioCentury | Sep 2, 2004
Financial News

Zars raises $19 million

...by Draper Fisher Jurvetson. Other investors included ePlanet Ventures; CDIB BioScience; Wasatch Venture Fund; and Tenex...
BioCentury | Jun 28, 2004
Financial News

Virogenomics spins out Artielle

...companies. Artielle also raised $4 million in a series A round with Sanderling; UV Partners; Tenex...
BioCentury | May 28, 2002
Company News

ESP Pharma, Wyeth deal

...million in 2001 sales, include Cardene IV for hypertension, Sectral for hypertension and ventricular arrhythmias, Tenex...
BioCentury | May 22, 2002
Financial News

ESP Pharma raises $28 million

...million in 2001 sales, include Cardene IV for hypertension, Sectral for hypertension and ventricular arrhythmias, Tenex...
BioCentury | Jan 3, 2002
Financial News

Myogen raises $14 million

...Perseus-Soros BioPharmaceutical Fund; China Development Industrial Bank; Hunt Ventures; Silicon Valley Bank; and affiliates of Tenex...
Items per page:
1 - 10 of 13